Medication info
Mebid Tablet (Glimiperide)

Mebid Tablet (Glimiperide)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
NBK Pharma Co., Ltd.
Appearance
Green rectangular tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Approval status
Active

MFDS item code 202002116 · Approved 2020.03.26 · Insurance code 054800840

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Adjust individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. This medicine should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received medication, initiate treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional benefit with doses above 4 mg, but some patients have achieved better metabolic control with an increase to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Secondary dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral antihyperglycemic agent to this medicine There is no precise dose equivalence between this medicine and other oral antihyperglycemic agents. When switching from another oral antihyperglycemic agent to this medicine, it is recommended to follow the procedure described under Initial dose. That is, initiate treatment at 1 mg daily and adjust the dose at 1 ~ 2 week intervals. The potency and duration of action of the previous medication should be taken into account. 4) Dose adjustment during treatment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate intake of sugar. Despite successful management initially, hypoglycemia may recur during treatment with sulfonylureas. Therefore, patients should be closely monitored. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization may sometimes be necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and initiate insulin at a low dose, increasing it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas such as glyburide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level can be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for glycemic control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Ingredients

Manufacturer
NBK Pharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. Patients may take this medication alone while following a diet and exercise regimen. If blood sugar control is not sufficient with monotherapy, it can be taken in conjunction with insulin or other oral hypoglycemic agents. Especially when blood sugar control is difficult with sulfonylureas or metformin monotherapy, combining this medication with metformin can be beneficial. This medication is effective in managing type 2 diabetes by enhancing blood sugar control abilities.

How to take

Adult dose

Adjust individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. This medicine should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received medication, initiate treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional benefit with doses above 4 mg, but some patients have achieved better metabolic control with an increase to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Secondary dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral antihyperglycemic agent to this medicine There is no precise dose equivalence between this medicine and other oral antihyperglycemic agents. When switching from another oral antihyperglycemic agent to this medicine, it is recommended to follow the procedure described under Initial dose. That is, initiate treatment at 1 mg daily and adjust the dose at 1 ~ 2 week intervals. The potency and duration of action of the previous medication should be taken into account. 4) Dose adjustment during treatment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate intake of sugar. Despite successful management initially, hypoglycemia may recur during treatment with sulfonylureas. Therefore, patients should be closely monitored. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization may sometimes be necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and initiate insulin at a low dose, increasing it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas such as glyburide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level can be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for glycemic control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Precautions

This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or those who are comatose. It is also safer not to administer it to patients who have previously had allergic reactions to this medication or any of its components. In patients with severely impaired liver or kidney function, it is recommended to switch to insulin therapy instead of using this medication. Pregnant women, women who may become pregnant, and breastfeeding mothers should not take this medication. Patients with severe infections, or those before and after surgery or after severe trauma, should also be treated with insulin. Caution is needed if gastrointestinal disorders such as diarrhea or vomiting occur, as there may be a risk of hypoglycemia due to poor food absorption. This medication contains lactose and should not be given to patients with lactose intolerance or specific genetic metabolic disorders. During the first week of treatment, there is a high risk of hypoglycemia, so blood sugar levels should be closely monitored. Particularly, elderly patients, those with poor nutritional status, irregular eaters, individuals with an imbalance between exercise and diet, and those consuming alcohol should take extra caution against hypoglycemia. Patients with reduced kidney or liver function, or those with other endocrine diseases may also respond sensitively to this medication, requiring careful management. This medication can cause hypoglycemia, with symptoms such as headaches, severe hunger, nausea, fatigue, anxiety, confusion, drowsiness, and loss of consciousness. If hypoglycemia occurs, it is essential to consume food containing sugar immediately, and in severe cases, treatment in a hospital is necessary. During initial administration, symptoms such as blurred vision, gastrointestinal disturbances, liver dysfunction, blood abnormalities, and allergic reactions may occur, so if any unusual symptoms arise, patients should inform their healthcare provider. This medication should be consistently taken with dietary changes and exercise for blood sugar control, and sudden lifestyle changes or illness should be discussed with a doctor. When taken with other medications, there may be an effect on blood sugar control, so patients must inform their healthcare provider about any other medications they are taking. Special attention is needed for interactions with beta-blockers, certain antibiotics, and steroids. In case of overdose, severe hypoglycemia may occur, requiring immediate emergency treatment and appropriate measures such as inducing vomiting or gastric lavage. The safety of this medication has not been established in children, so it is not recommended for use in individuals under 18 years of age. In the elderly, impaired kidney function may slow the excretion of this medication, so dosage adjustment and caution are necessary. Keep the medication out of reach of children and store it in its original container to maintain the quality of the medication.

Side effects

  • Hypoglycemia
  • headache
  • severe hunger
  • nausea
  • vomiting
  • fatigue
  • sleep
  • sleep disorders
  • anxiety
  • aggression
Show 68 more
  • decreased concentration
  • decreased agility or motivation
  • depression
  • confusion
  • speech abnormalities
  • aphasia
  • visual impairment
  • tremor
  • incomplete paralysis
  • perceptual disturbances
  • dizziness
  • weakness
  • loss of self-control
  • temporary mental confusion
  • cerebral convulsions
  • drowsiness
  • loss of consciousness
  • coma
  • shallow breathing
  • bradycardia
  • sweating
  • cold and clammy skin
  • tachycardia
  • hypertension
  • palpitations
  • angina
  • deep vein thrombosis
  • blurred vision
  • fullness in the upper abdomen
  • pressure sensation
  • abdominal pain
  • diarrhea
  • increased liver enzymes
  • abnormal liver function
  • bile secretion disorder
  • jaundice
  • hepatitis
  • thrombocytopenia
  • leukopenia
  • hemolytic anemia
  • erythrocytopenia
  • granulocytopenia
  • agranulocytosis
  • pancytopenia
  • itching
  • hives
  • rash
  • respiratory distress
  • hypotension
  • shock
  • anaphylaxis
  • angioedema
  • skin and mucous membrane syndrome
  • allergic vasculitis
  • phototoxic reactions of the skin
  • decreased serum sodium concentration
  • taste disturbances
  • hair loss
  • weight gain
  • dizziness
  • abnormal liver function
  • abdominal pain
  • arthralgia
  • dyspepsia
  • facial swelling
  • erectile dysfunction
  • flushing
  • gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to store it at room temperature between 1°C and 30°C. Proper storage will safely maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Green rectangular tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.